Clascoterone's full trial results are expected by mid-July 2026, but skepticism exists about timely release. Clascoterone is available at 5% from some telehealth companies.
A satirical post humorously discusses a fictional hair regrowth drug called PP405, with users joking about its effectiveness and bizarre presentation. The conversation includes humorous reactions and references to the absurdity of the content.
The user experienced side effects from spironolactone and is seeking alternatives for androgenetic alopecia (AGA), considering saw palmetto but unsure of its effectiveness. They are also exploring the possibility of using topical spironolactone, despite availability challenges.
A user reported that after experiencing hair thinning, they started using finasteride in 2024 and later began GHK-Cu peptide injections in March 2026, which they believe stopped their hair loss and made their hair feel thicker. The user shared their experience despite receiving criticism for not solely endorsing finasteride.
A user discusses their habit of analyzing others' hair due to their own hair thinning at 18. Another user mentions starting finasteride in 2010 and still having a full head of hair.
The conversation is about using Vitamin B5, B6, and Biotin for hair health, with a focus on whether to take these supplements separately when using topical finasteride products. One user dismisses the effectiveness of multivitamins.
The conversation discusses Pyrilutamide for hair loss, with skepticism about its legitimacy and mentions of an upcoming press release from Kintor. It also references ongoing trials and includes links for further information.
A user received a prescription for Dutasteride 0.5 in Europe and asked about the brand. Replies confirmed the brand's quality and suggested using the cheapest gelatin capsule form.
Magnesium L-Threonate may help treat balding by reducing DKK-1 expression without affecting DHT. Users discuss its potential effectiveness and application methods, with some considering trying it topically.